In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Current treatment regimens for pancreatic ductal adenocarcinoma (PDAC) yield poor 5-year survival, emphasizing the critical need to identify druggable targets essential for PDAC maintenance. We developed an unbiased and in vivo target discovery approach to identify molecular vulnerabilities in low-passage and patient-derived PDAC xenografts or genetically engineered mouse model-derived allografts. Focusing on epigenetic regulators, we identified WDR5, a core member of the COMPASS histone H3 Lys4 (H3K4) MLL (1-4) methyltransferase complex, as a top tumor maintenance hit required across multiple human and mouse tumors. Mechanistically, WDR5 functions to sustain proper execution of DNA replication in PDAC cells, as previously suggested by replication stress studies involving MLL1, and c-Myc, also found to interact with WDR5. We indeed demonstrate that interaction with c-Myc is critical for this function. By showing that ATR inhibition mimicked the effects of WDR5 suppression, these data provide rationale to test ATR and WDR5 inhibitors for activity in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 1×
“For patients who are not candidates for surgery, two drugs, gemcitabine and erlotinib, were first approved for PDAC treatment by the US FDA, with two novel regimens approved in recent years, FOLFIRINOX and nab-paclitaxel (Conroy et al., 2011; Von Hoff et al., 2013).”
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationHingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Self-citationPancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Self-citationOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationRestoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“The pSICO and pSICO-Flpo were made by Dr. Tyler Jacks (Ventura et al., 2007).”
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683
Research works printed but not linked: 45
- Almoguera, 1988, Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, Cell, 53, 549, 10.1016/0092-8674(88)90571-5 · DOI · Paper page
- Baratta, 2015, An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma, Proc. Natl. Acad. Sci. USA, 112, 232, 10.1073/pnas.1422165112 · DOI · Paper page
- Bonnefoix, 2010, Revisiting the concept of phenotypically distinct malignant pancreatic stem-cell subsets based on limiting dilution transplantation assays, J. Clin. Oncol., 28, e89, 10.1200/JCO.2009.25.0282 · doi:10.1200/jco.2009.25.0282
- Campaner, 2012, Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance, Cell Div., 7, 6, 10.1186/1747-1028-7-6 · DOI
- Cao, 2014, Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia, Mol. Cell, 53, 247, 10.1016/j.molcel.2013.12.001 · DOI · Paper page
- Chen, 2015, Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation, Sci. Rep., 5, 8293, 10.1038/srep08293 · DOI
- Dang, 1999, c-Myc target genes involved in cell growth, apoptosis, and metabolism, Mol. Cell. Biol., 19, 1, 10.1128/MCB.19.1.1 · DOI · Paper page
- Dominguez-Sola, 2007, Non-transcriptional control of DNA replication by c-Myc, Nature, 448, 445, 10.1038/nature05953 · DOI · Paper page
- Gaillard, 2015, Replication stress and cancer, Nat. Rev. Cancer, 15, 276, 10.1038/nrc3916 · DOI · Paper page
- Hu, 2009, ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays, J. Immunol. Methods, 347, 70, 10.1016/j.jim.2009.06.008 · DOI · Paper page
- Hubert, 2013, Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A, Genes Dev., 27, 1032, 10.1101/gad.212548.112 · DOI · Paper page
- Ischenko, 2014, Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas, Proc. Natl. Acad. Sci. USA, 111, 3466, 10.1073/pnas.1319911111 · DOI · Paper page
- Ishizawa, 2010, Tumor-initiating cells are rare in many human tumors, Cell Stem Cell, 7, 279, 10.1016/j.stem.2010.08.009 · DOI · Paper page
- Kim, 2014, A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer, Mol. Cell, 54, 613, 10.1016/j.molcel.2014.03.043 · DOI · Paper page
- König, 2007, A probability-based approach for the analysis of large-scale RNAi screens, Nat. Methods, 4, 847, 10.1038/nmeth1089 · DOI · Paper page
- Krattenmacher, 2014, Synthetic lethality screen identifies SMC2 as a new target gene in pancreatic cancer, Pancreatology, 13, S66, 10.1016/j.pan.2014.05.605 · doi:10.1016/j.pan.2014.05.605
- Langmead, 2009, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, Genome Biol., 10, R25, 10.1186/gb-2009-10-3-r25 · DOI · Paper page
- Li, 2009, The Sequence alignment/map (SAM) format and SAMtools, Bioinformatics, 25, 2078, 10.1093/bioinformatics/btp352 · DOI · Paper page
- Liu, 2010, Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint, Nature, 467, 343, 10.1038/nature09350 · DOI · Paper page
- Meacham, 2009, In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression, Nat. Genet., 41, 1133, 10.1038/ng.451 · DOI · Paper page
- Moffat, 2006, A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen, Cell, 124, 1283, 10.1016/j.cell.2006.01.040 · DOI · Paper page
- Morris, 2010, Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice, J. Clin. Invest., 120, 508, 10.1172/JCI40045 · DOI · Paper page
- Murga, 2011, Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors, Nat. Struct. Mol. Biol., 18, 1331, 10.1038/nsmb.2189 · DOI · Paper page
- Omura, 2009, Epigenetics and epigenetic alterations in pancreatic cancer, Int. J. Clin. Exp. Pathol., 2, 310
- Possik, 2014, Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition, Cell Rep., 9, 1375, 10.1016/j.celrep.2014.10.024 · DOI
- Prevo, 2012, The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy, Cancer Biol. Ther., 13, 1072, 10.4161/cbt.21093 · DOI · Paper page
- Quintana, 2008, Efficient tumour formation by single human melanoma cells, Nature, 456, 593, 10.1038/nature07567 · DOI · Paper page
- Sahai, 2014, BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen, Mol. Cancer Ther., 13, 1907, 10.1158/1535-7163.MCT-13-0925 · DOI · Paper page
- Schlabach, 2008, Cancer proliferation gene discovery through functional genomics, Science, 319, 620, 10.1126/science.1149200 · DOI · Paper page
- Scholl, 2009, Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells, Cell, 137, 821, 10.1016/j.cell.2009.03.017 · DOI · Paper page
- Schoppy, 2012, Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR, J. Clin. Invest., 122, 241, 10.1172/JCI58928 · DOI · Paper page
- Schuettengruber, 2011, Trithorax group proteins: switching genes on and keeping them active, Nat. Rev. Mol. Cell Biol., 12, 799, 10.1038/nrm3230 · DOI · Paper page
- Sears, 1999, Ras enhances Myc protein stability, Mol. Cell, 3, 169, 10.1016/S1097-2765(00)80308-1 · DOI · Paper page
- Silva, 2008, Profiling essential genes in human mammary cells by multiplex RNAi screening, Science, 319, 617, 10.1126/science.1149185 · DOI · Paper page
- Smith, 2011, The super elongation complex (SEC) and MLL in development and disease, Genes Dev., 25, 661, 10.1101/gad.2015411 · DOI · Paper page
- Stathis, 2010, Advanced pancreatic carcinoma: current treatment and future challenges, Nat. Rev. Clin. Oncol., 7, 163, 10.1038/nrclinonc.2009.236 · DOI · Paper page
- Stellas, 2014, Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer, J. Natl. Cancer Inst., 106, dju320, 10.1093/jnci/dju320 · DOI
- Steward, 2006, Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes, Nat. Struct. Mol. Biol., 13, 852, 10.1038/nsmb1131 · DOI · Paper page
- Sun, 2015, WDR5 supports an N-Myc transcriptional complex that drives a protumorigenic gene expression signature in neuroblastoma, Cancer Res., 75, 5143, 10.1158/0008-5472.CAN-15-0423 · DOI
- Trievel, 2009, WDR5, a complexed protein, Nat. Struct. Mol. Biol., 16, 678, 10.1038/nsmb0709-678 · DOI
- Ventura, 2004, Cre-lox-regulated conditional RNA interference from transgenes, Proc. Natl. Acad. Sci. USA, 101, 10380, 10.1073/pnas.0403954101 · DOI · Paper page
- Wang, 2009, Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II, Mol. Cell. Biol., 29, 6074, 10.1128/MCB.00924-09 · DOI · Paper page
- Yu, 1995, Altered Hox expression and segmental identity in Mll-mutant mice, Nature, 378, 505, 10.1038/378505a0 · DOI · Paper page
- Zender, 2008, An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer, Cell, 135, 852, 10.1016/j.cell.2008.09.061 · DOI · Paper page
- Zhou, 2009, Tumour-initiating cells: challenges and opportunities for anticancer drug discovery, Nat. Rev. Drug Discov., 8, 806, 10.1038/nrd2137 · DOI · Paper page
Cited by
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Byrne, A. T., Alférez, D. G., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.140 · Cited by 657
Self-citationIncreased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
Cascone, T., McKenzie, J. A., Mbofung, R. M., Punt, S., Wang, Z., Xu, C., Williams, L. J., Wang, Z., Bristow, C. A., Carugo, A., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.024 · Cited by 611
Self-citationAccurate and efficient detection of gene fusions from RNA sequencing data
Uhrig, S., Ellermann, J., Walther, T., Burkhardt, P., Fröhlich, M., Hutter, B., Toprak, U. H., Neumann, O., Stenzinger, A., Scholl, C., et al. (2021) · Genome Research · doi:10.1101/gr.257246.119 · Cited by 526
MYC protein interactors in gene transcription and cancer
Lourenco, C., Resetca, D., Redel, C., Lin, P., MacDonald, A. S., Ciaccio, R., Kenney, T. M. G., Wei, Y., Andrews, D. W., Sunnerhagen, M., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00367-9 · Cited by 347
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“Mice experiments using PDXs were derived as previously described (84).”
MethodSelf-citationMahadevan, K. K., McAndrews, K. M., LeBleu, V. S., Yang, S., Lyu, H., Li, B., Sockwell, A. M., Kirtley, M. L., Morse, S. J., Moreno Diaz, B. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.002 · Cited by 258
Self-citationSyndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer
Yao, W., Rose, J. L., Wang, W., Seth, S., Jiang, H., Taguchi, A., Liu, J., Yan, L., Kapoor, A., Hou, P., et al. (2019) · Nature · doi:10.1038/s41586-019-1062-1 · Cited by 214
Self-citationSynthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer
Genovese, G., Carugo, A., Tepper, J., Robinson, F. S., Li, L., Svelto, M., Nezi, L., Corti, D., Minelli, R., Pettazzoni, P., et al. (2017) · Nature · doi:10.1038/nature21064 · Cited by 131
Self-citationSynthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
“…cell lines as well as other potentially more physiologically relevant cancer model systems, such as three-dimensional organoid cultures (Sachs and Clevers 2014; Boj et al. 2015) or animal models of KRAS mutant tumors (Zender et al. 2008; Zuber et al. 2011; Beronja et al. 2013; Carugo et al. 2016).”
BackgroundChacón Simon, S., Wang, F., Thomas, L. R., Phan, J., Zhao, B., Olejniczak, E. T., Macdonald, J. D., Shaw, J. G., Schlund, C., Payne, W., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00224 · Cited by 76
Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective
Chen, X., Xu, J., Wang, X., Long, G., You, Q., & Guo, X. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00037 · Cited by 63
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
Peng, D. H., Kundu, S. T., Fradette, J. J., Diao, L., Tong, P., Byers, L. A., Wang, J., Canales, J. R., Villalobos, P. A., Mino, B., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1238 · Cited by 53
Self-citationPatient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
Rizzo, G., Bertotti, A., Leto, S. M., & Vetrano, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01970-2 · Cited by 51
Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition
Yan, L., Tu, B., Yao, J., Gong, J., Carugo, A., Bristow, C. A., Wang, Q., Zhu, C., Dai, B., Kang, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3792 · Cited by 48
Self-citation
Metadata
- Authors
- Carugo, A., Genovese, G., Seth, S., Nezi, L., Rose, J. L., Bossi, D., Cicalese, A., Shah, P. K., Viale, A., Pettazzoni, P. F., Akdemir, K. C., Bristow, C. A., Robinson, F. S., Tepper, J., Sanchez, N., Gupta, S., Estecio, M. R., Giuliani, V., Dellino, G. I., Riva, L., Yao, W., Di Francesco, M. E., Green, T., D’Alesio, C., Corti, D., Kang, Y., Jones, P., Wang, H., Fleming, J. B., Maitra, A., Pelicci, P. G., Chin, L., DePinho, R. A., Lanfrancone, L., Heffernan, T. P., & Draetta, G. F.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 16
- Issue
- 1
- Pages
- 133-147
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2422923474
- Cited by
- 141
- References
- 17
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.